DermTech Inc

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in La Jolla, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

DermTech sees growth in test volumes despite revenue decline

DermTech's Q4 performance reflects growth in coverage and billable sample volumes, despite a decline in total revenue.
The company's strengths lie in expanding market acceptance, stabilized ASPs, and efforts to reduce payer friction.
Challenges include revenue diversification, leadership transition, and uncertainties in ASP trends, while opportunities exist in payer discussions and operational enhancements.

DermTech Inc reports revenue growth and volume increases in Q1

DermTech Inc's Q1 2023 performance showed revenue growth and volume increases, with a focus on stabilizing ASP and driving reimbursed volumes.
While facing challenges with flat DMT volumes and frustration over national payers' views, the company is optimistic about broader acceptance and cost-saving initiatives.
Opportunities lie in TRUST 2 study results influencing payer discussions, momentum with other payers, and targeting physicians with aligned payer mixes.

DermTech reports mixed Q2 results, focuses on revenue growth

DermTech faces challenges with flat DMT volumes and higher operating expenses but is leveraging strengths in insurance partnerships and revenue prioritization.
Opportunities lie in the growth potential of the DMT, expanding coverage, and optimizing sales strategies for revenue enhancement.
Overall, DermTech's financial performance in Q2 2023 reflects a strategic focus on revenue growth amidst operational challenges.

DermTech reports improved Q3 performance, eyes TRUST 2 study impact

DermTech's Q3 2023 performance showcased positive trends in ASP, revenue, and operational efficiency, despite a net loss.
Strategic strengths in sales team alignment, clinical value emphasis, and liquidity position the company well for future growth.
Challenges lie in maintaining test volumes, sustaining margins, and addressing cost reductions and effective payer communications.
Opportunities include TRUST 2 study results, legislative efforts, and focusing on reimbursed tests for revenue growth.

DermTech Inc reports robust Q4 growth and strategic cost reductions

DermTech Inc's Q4 2023 performance showcased strong growth in key metrics and financial health.
The company's focus on precision genomics and cost efficiencies positions it well for future success.
Challenges lie in sustaining revenue growth, optimizing expenses, and engaging payers effectively.
Opportunities abound in expanding reimbursed tests, revenue, and market presence for long-term growth.

The full company name is Design Media Technology, Inc.

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that Geisinger Health System (“Geisinger”) has issued a positive medical benefit policy for its Commercial and Medicare Business Segment for the DermTech Pigmented Lesion Assay (“PLA”). DermTech's PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99% negative predicti

DermTech Receives Positive Medical Coverage by Geisinger Health System

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ:DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech management will present at the ICR Conference 2021 on Thursday, January 14, 2021 at 10:00 a.m. Eastern time. Interested parties may access a live webcast of the presentation and, for 90 days following the ICR Conference 2021, an archived webcast of the presentation through the “Investor Relations” section

DermTech Management to Present at the ICR Conference 2021

DermTech (DMTK) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

DermTech (DMTK) in Focus: Stock Moves 6% Higher

Why DermTech Stock Soared Today

DermTech's PLA stickers can help to diagnose melanoma despite being lower cost, more accurate, and less invasive compared to standard surgical biopsies.With 4-4.5mil surgical biopsies per year and an average reimbursement of $760, the TAM is more than $3bil.

DermTech: Stickers To Diagnose Cancer

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline results from its TRUST Study of the company's non-invasive melanoma rule-out test, the Pigmented Lesion Assay (the “PLA”). The TRUST study is a long-term follow-up study of pigmented skin lesions that tested negative for melanoma with the PLA. It was designed to assess long-term outcomes of PLA negative tes

DermTech Announces Topline Results of its TRUST Study: Results Confirm the High Negative Predictive Value of the PLA at 99% and Find No Significant Adverse Outcomes After Long-Term Follow-Up of PLA Negative Tests

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its inclusion in two CME sessions, at the Fall Clinical Dermatology Virtual Grand Rounds (the “FCVGR”) and the 23rd Annual Mount Sinai Winter Symposium “Advances in Medical and Surgical Dermatology” (the “Mount Sinai Symposium”). The FCVGR presentation was led by Laura K Ferris, MD, PhD of the University of Pittsburgh

DermTech's Melanoma Test Included in Two Continuing Medical Education (“CME”) Sessions at 2020 Fall Clinical Virtual Grand Rounds and Mount Sinai Winter Symposium

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entered into an agreement, effective February 1, 2021, with Blue Shield of California for reimbursement coverage for all of its products. Blue Shield of California has approximately 3.7 million covered lives in California through its Commercial PPO/EPO, Medicare Advantage PPO, Commercial HMO and Medicare Advanta

DermTech Enters Into Agreement With Blue Shield of California

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the presentation of a precision medicine focused session at the fourth annual Dermatology Drug Development Summit. Held virtually this year, the Dermatology Drug Development Summit is the only industry-focused meeting dedicated to innovating, accelerating, and sharing pharmaceutical best practice on the development and

DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entered into an agreement, effective November 3, 2020, with Blue Cross Blue Shield of Illinois for its Commercial PPO and Medicare Advantage membership. DermTech's PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99% negative predictive value (“NPV”), meaning

DermTech Enters Agreement with Blue Cross Blue Shield of Illinois

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech Presents New Clinical Research Abstract at the 2020 Fall Clinical Dermatology Conference

DermTech Presents New Clinical Research Abstract at the 2020 Fall Clinical Dermatology Conference

Innovative Industrial Properties

Trupanion

Great things appear to be in store for these rising stars.

Buying These 3 Stocks Could Make You Rich Over the Next Decade

DermTech, Inc. (DMTK) CEO John Dobak on Q3 Results - Earnings Call Transcript

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial results as of and for the quarter ended September 30, 2020. Third Quarter Highlights Assay revenues of $1.2 million for the third quarter of 2020, a 220% increase compared to the third quarter of 2019 and a 90% sequential increase over the second quarter of 2020. Billable sample volume of approximate

DermTech Reports Third Quarter 2020 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that Company management will participate in the following upcoming investor conferences: Stifel 2020 Virtual Healthcare Conference Presenting on Wednesday, November 18, 2020 at 1:20 p.m. Eastern time Canaccord Genuity Virtual MedTech & Diagnostics Forum Presenting on Thursday, November 19, 2020 at

DermTech to Participate in Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech to Announce Third Quarter 2020 Financial Results on November 10, 2020

DermTech to Announce Third Quarter 2020 Financial Results on November 10, 2020

Semler Scientific

Discover how these three companies could change the face of healthcare.

3 Healthcare Stocks to Watch

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech Announces Appointment of Chief Scientific Officer

DermTech Announces Appointment of Chief Scientific Officer

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc.

DermTech, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that as part of the annual reconstitution of the Russell stock indexes, DermTech has been selected to be added to the Russell 2000® Index effective June 26, 2020. “We are pleased to have earned our inclusion in the Russell 2000® Index, one of the most widely cited performance benchmarks for small-cap companies,” said J

DermTech Announces Inclusion in the Russell 2000 Index

Blink Charging

Cocrystal Pharma

Tetraphase Pharmaceuticals

This week has been a successful one for markets, with the S&P 500 entering positive territory on the year. If you’re looking to hedge the rally, our deep learning algorithms have identified several top shorts for your portfolio.

Top Companies To Short As Stock Market Continues To Rally

Shares of precision dermatology company DermTech Inc (NASDAQ: DMTK) are rallying Thursday after receiving Medicare coverage for its diagnostic test to rule out skin cancer.

News for DermTech Inc Stock (DMTK)